NCT03927885 is a Phase 2, PHASE3 clinical trial of Quality-of-Life Assessment in Advanced Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT03927885?

NCT03927885 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT03927885?

Interventions in NCT03927885: Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Waiting List.

What condition does NCT03927885 study?

NCT03927885 studies Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm.

Is NCT03927885 still recruiting?

NCT03927885 is currently active, enrolled. Last updated 19 February 2026.

Last reviewed 2026-02-19 · How we verify

NCT03927885

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

Active, enrolled Phase 2, PHASE3 Last updated 19 February 2026

What this trial tests

Phase 2, PHASE3 trial testing Placebo Administration in Advanced Malignant Solid Neoplasm in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 March 2019

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2, PHASE3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	100
Start date	30 March 2019
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

Placebo Administration — full drug profile →
Quality-of-Life Assessment
Questionnaire Administration
Waiting List

Conditions studied

Advanced Malignant Solid Neoplasm — all drugs for Advanced Malignant Solid Neoplasm →
Metastatic Malignant Solid Neoplasm — all drugs for Metastatic Malignant Solid Neoplasm →
Recurrent Malignant Solid Neoplasm — all drugs for Recurrent Malignant Solid Neoplasm →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Advanced Malignant Solid Neoplasm or Metastatic Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II/III trial studies an open labeled placebo to see how well it works compared with waitlist control in reducing cancer related fatigue in patients with cancer that has spread to other places in the body. A placebo is not a drug and is not designed to treat any disease or illness. Recent studies have found that cancer related fatigue symptoms in cancer survivors are improved with open labeled placebo (that is, patients know they are taking a placebo). It is not yet known how well an open labeled placebo works when compared with waitlist control in reducing cancer related fatigue.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Open-Label Placebo for the Treatment of Cancer-Related Fatigue in Patients with Advanced Cancer: A Randomized Controlled Trial.
Yennurajalingam S, Azhar A, Lu Z, Rodriguez AJ, et al · · 2022 · cited 18× · PMID 36106759 · DOI 10.1093/oncolo/oyac184

Verify or expand the search:

Other trials of Quality-of-Life Assessment

Trials testing the same drug.

NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
NCT06710418 — Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functi · NA · recruiting
NCT06500481 — Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE- · Phase 3 · recruiting
NCT05539365 — Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast · Phase 2 · withdrawn
NCT06526897 — Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Ext · NA · not yet recruiting

Other recruiting trials for Advanced Malignant Solid Neoplasm

Currently open trials in the same condition.

NCT07141407 — Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and T · NA · recruiting
NCT07189195 — TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory · Phase 1 · recruiting
NCT07174661 — Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid · NA · recruiting
NCT06223542 — Studying TAK-243 in Patients With Advanced Cancer · Phase 1 · recruiting
NCT06311214 — Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastati · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03927885 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 19 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03927885.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing